Vertex Pharma (VRTX) Tops Q1 EPS by 14c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Vertex (VRTX) PT Raised to $202 at RBC Capital
April 27, 2018 9:01 AM EDTRBC Capital raised its price target on Vertex (NASDAQ: VRTX) to $202.00 (from $199.00) while maintaining a Outperform rating.
... MoreVertex Pharma (VRTX) Begins Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as Triple Combination Regimen for People with Cystic Fibrosis
April 26, 2018 4:37 PM EDTVertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that it is initiating two Phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF). The first Phase 3 study will evaluate approximately 360 people with CF who have one copy of the... More
